Je was op zoek naar: biodefense (Frans - Engels)

immunotherapie de biodefense
immunotherapeutics for biodefense

working group on civilian biodefense.
ellis t. toward safer needles.

agents therapeutiques immunologiques destines a la biodefense
immunotherapeutics for biodefense

• la george mason university à manassas, comprend le center for biodefense.
• george mason university, manassas, includes the center for biodefense.

« u.s. biodefense wholly owned portfolio company stem cell research institute, inc.
"u.s. biodefense wholly owned portfolio company stem cell research institute, inc.

quelques publications (biotechnology: impact on biological warfare and biodefense; biosecurity and bioterrorism 2003.
some publications (biotechnology: impact on biological warfare and biodefense; biosecurity and bioterrorism 2003.

biosecurity and bioterrorism: biodefense strategy, practice, and science, 6(4), 299-307
biosecurity and bioterrorism: biodefense strategy, practice, and science, 6(4), 299-307

intervenants consultés pour finaliser la liste des priorités de l'irscip membres de l’Équipe canadienne de recherche d'intervention rapide (erir) lorne babiuk, président, conseil consultatif de l’institut, institut des maladies infectieuses et immunitaires des irsc alan bernstein, président, instituts de recherche en santé du canada (irsc) judith bossé, vice-présidente, science, agence canadienne d'inspection des aliments colleen flood, directrice scientifique, institut des services et des politiques de la santé des irsc john frank, directeur scientifique, institut de la santé publique et des populations des irsc jean marion, directeur, affaires scientifiques, rx&d : les compagnies de recherche pharmaceutique du canada frank plummer, directeur général, agence de santé publique du canada bhagirath singh, directeur scientifique, institut des maladies infectieuses et immunitaires des irsc isaac sobol, médecin hygiéniste en chef, conseil des médecins hygiénistes en chef ernest t. takafuji, directeur, office of biodefense research, national institute of allergy and infectious diseases, national institutes of health aubrey tingle, président, fondation michael smith pour la recherche en santé michael vandergrift, directeur, division des politiques des sciences de la santé, santé canada
stakeholders consulted to finalize the ppsri priorities canadian rapid research response team (c3rt) members lorne babiuk, chair, institute advisory board, cihr institute of infection and immunity alan bernstein, president, canadian institutes of health research (cihr) judith bossé, vice-president, science, canadian food inspection agency colleen flood, scientific director, cihr institute of health services and policy research john frank, scientific director, cihr institute of population and public health jean marion, director, scientific affairs, rx&d (canada's research based pharmaceutical companies) frank plummer, director general, public health agency of canada bhagirath singh, scientific director, cihr institute of infection and immunity isaac sobol, chief medical officer of health, council of chief medical officers of health ernest t. takafuji, director, office of biodefense research, national institute of allergy and infectious diseases, national institutes of health aubrey tingle, president, michael smith foundation for health research michael vandergrift, director, health science policy division, health canada